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One-pot multi-component synthesis of tri and tetra-substituted coumarin-imidazole conjugates have been achieved in 
good to excellent yield under conventional and microwave methods in optimized catalyst condition. Further, they have been 
evaluated for antimicrobial activity against Gram positive Bacillus flexus and Gram negative Pseudomonas Spp. bacterial 
strains and two strains of fungi Scopulariopsis spp. and Aspergillus tereus organisms. The results of microbial activity are 
promising against tested organisms. The molecular docking study has been performed for all the compounds and docking 
scores are excellent. Synthesized compounds have been characterized by IR, NMR, mass and a few of them by single crystal 
X-ray analysis. 
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Imidazole ring system is known for active scaffold in 
biomolecules and is the integral part of some naturally 
occurring molecules such as histadine, histamines, 
amino acids, component of DNA base and Vit-B12,  
etc. Generally, this class of compounds attracted 
importance towards inhibitory activities against p38α1. 
cyclooxygenase-22, transfer growth factor β1 (TGF-
β1), type І active receptor like kinase3, and also against 
biosynthesis of inter-leukine-І4. Imidazole derivative 
also exhibit wide range of biological activities such as 
fungicides, herbicides5, plant growth regulators6 and 
therapeutic agents7. The N-substituted imidazoles are 
class of heterocyclic scaffolds having important 
pharmacological properties such as antimicrobial8-10, 
antiparasitic11, antimalarial12, antihistaminic13, anti-
inflammatory14, analgesic15, antitubercular16, 
antiprotozoal17 and anthelmintics18. On the other hand 
imidazole nucleus is essential moiety for the most ionic 
liquids19, chiral auxiliaries20,21 and chiral ligands22-24. 
Natural products exhibit several biological 
activities that can be of therapeutic actions in 
treatment of various diseases. Coumarin is one of 
such natural product which has been isolated from a 
variety of plant sources to assess their potential 
therapeutic uses25. Thus, the biological investigation 
of coumarin derivatives shows the engrossment of 
several path ways by which it showed several 
biological activities including: anticancer26,27, anti-
HIV28,29, anticoagulant30, antimicrobial31, antioxidant32 
and anti-inflammatory33 activities. Recently, many 
conjugate molecules with coumarin ring system have 
been designed and synthesized. In this line the 
coumarin derivatives conjugated with nitrogen 
containing heterocyclic moieties, such as triazolo and 
pyridine were synthesized and these hybrids proved to 
possess antibacterial and antifungal activities34,35. The 
promising therapeutic perspectives of both the 
heterocycles, we have considered molecular 
hybridization strategy for the synthesis of target 
compounds. 
In this article we have developed a simple, efficient 
and general method for the synthesis of coumarin 
conjugate structures under conventional as well as 
microwave (MW) methods and carried out 
pharmacological activities as well as molecular 
docking study. 
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Results and Discussion 
Chemistry 
In literature there are many synthetic methods for 
the synthesis of imidazoles, among these microwave 
assisted method has driven considerable much 
attention36,37. The C-4 position of coumarin ring 
bearing five membered imidazole derivatives are not 
available in the literature. Here, we have designed  
and synthesized C4-coumarin directly linked with  
C2-imidazole via multi-component reaction. The 
synthetic strategy followed for the synthesis of 
coumarin-imidazole conjugates are out lined in 
Scheme I. Reaction of 4-formylcoumarins 1 38, 1,  
2-diketone 2, substituted anilines 3 with ammonium 
acetate in presence of acid catalysts to furnished 
desired coumarin-imidazole conjugates 4a-m in good 
yield (>65%) under conventional as well as 
microwave methods. Among two methods, MW 
method afforded excellent results in terms of yield 
and time. Further, the reaction was performed in 
different solvents and catalysts to optimize the 
condition to afford compound 4. The optimization 
results have shown that acetic acid alone as catalyst 
and solvent afforded excellent yield as well as purity 
(Table I). Similarly, compounds 6a-f were 
synthesized by using above optimized reaction 
condition in good to excellent yield and synthetic 
pathway is outlined in Scheme II. Further, compounds 
6a-f were converted to corresponding esters 7a-f by 
the reaction of methanol in sulphuric acid. Structures 
of all the synthesized compounds 4a-m, 6a-f and 7a-f 
given in Table II confirmed by spectral analysis and 
some of them by single X-ray crystal study. 
 
X-ray diffraction studies 
The two coumarin imidazole hybrids single crystals 
4b (Figure 1) and 7f (Figure 2) were grown in 
dichloromethane (DCM). The crystals of suitable 
quality were mounted in glass capillaries, cooled to 0 
and 100 K. The intensity data were collected on a 
Bruker Nonius SMART APEX CCD detector system 
with Mo-sealed Siemens ceramic diffraction tube (λ = 
0.71073) and a highly oriented graphite 
monochromator operating at 50 kV and 30 mA. The 
data was collected on a hemisphere mode and 
processed with SAINT-Plus, while the empirical 
absorption corrections were made using SADABS39. 
The structures were solved by direct method using  
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Scheme I — Synthesis of coumarin conjugates 4a-m 
 
Table I — Optimized condition for the synthesis of compound 4a 
Entry Catalysts Solvent Ratio Conventional Microwave 
Temp. (°C) Time (h) Yield (%) Temp. (°C) Time (min) Yield (%)a 
1 Acetic acid Ethanol 1:1 80 8 55 70 5 83 
2 Acetic acid PEG-400 1:2 100 8 62 120 5 78 
3 Acetic acid DMF 1:1 80 8 64 100 5 85 
4 Acetic acid Acetic acid − 90 8 85 100 5 93 
5 Silica H2SO4 Ethanol 1:1 80 5 54 70 4 69 
6 Silica H2SO4 PEG-400 1:2 100 5 60 120 4 75 
7 Silica H2SO4 DMF 1:1 80 5 62 100 3 75 
8 Zinc Oxide Ethanol 2:1 110 8 45 100 6 56 
9 Zinc Oxide PEG-400 2:2 120 8 52 120 6 60 
10 Zinc Oxide DMF 2:1 100 8 55 100 6 55 
aIsolated yields 
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Scheme II — Synthesis of coumarin conjugates 6a-f and 7a-f 
 
Table II — Synthesized coumarin-imidazole conjugates 4a-m, 6a-f and 7a-f 
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SHELXTL package and refined by full matrix  
least-squares method based on F2 using SHELX97 
program40. All the non-hydrogen atoms were refined 
anisotropically. The hydrogen atoms were included  
in the ideal positions with fixed isotropic U values 
and were riding with their respective non-hydrogen 
atoms. 
Substitution on the coumarin ring may affect the 
molecular arrangement of coumarin imidazole 
conjugates because of the steric repulsion. The 
coumarin is planar but exhibits slightly wave 
deformation. In particular compound 4b structure is 
found in triclinic setting, space group P-1, with Z=8. 
Its asymmetric unit contains a coumarin ring, 
imidazole and two phenyl groups. As shown in 
Figure 1 and Figure 2, three phenyl groups are 
oriented in slightly perpendicular geometry. Similarly, 
structure 7f is found in the monoclinic setting, space 
group P121/c1, with Z=4.Crystal data and structure 
refinement parameters of compounds 4b and 7f are 
summarized in Table III. 
 
Biological Screening 
Antimicrobial Activity 
Coumarin and imidazole derivatives are promising 
target compounds for antibacterial as well antifungal 
activity. Thus, all the synthesized scaffolds 4a-m, 6a-
f and 7a-f were screened for their antibacterial 
activity against Gram positive Bacillus flexus and 
Gram negative Pseudomonas Spp. bacterial strains. 
Similarly, two strains of fungi Scopulariopsis spp. and 
Aspergillustereus via agar well diffusion 
method.Ciprofloxacin and Nystatin are most effective 
antimicrobial agents and were used as reference 
drugs. All the strains were incubated at 37°C for 
about 48 h by inoculation into nutrient broth (Difco). 
The molten nutrient agar was inoculated with 100 µL 
of the inoculums and poured into the petri plate. The 
diameter of inhibition zones (in mm) was determined 
and MIC of the tested compounds was statistically 
determined by Turkey’s fair wise test. A stock 
solution of the newly synthesized compounds in 
DMSO was prepared and incorporated in sterilized 
liquid medium. After medium was solidified, a well 
was made in the plates with the help of cup-borer 
(0.85 cm) after 48 h. 
 
 
 
Figure 1 — ORTEP diagram of compound 4b 
 
 
 
Figure 2 — ORTEP diagram of compound 7f 
 
 
 
Table III — The crystal data and structure refinement  
parameters of compounds 4b and 7f 
Compd 4b 7f 
Formula C31H22N2O2 C36H24N2O4 
M 454 548.59 
T/K 296(2) K 296(2) K 
Crystal system triclinic monoclinic 
Space group P -1 P 1 21/c 1 
a/Ǻ 14.4026(3) 12.8057(4) 
b/Ǻ 18.2380(4) 28.4281(10) 
c/Ǻ 19.8452(5) 7.9865(3) 
α/(°) 93.9030(10) 90° 
β/(°) 110.3220(10) 101.402(2)° 
γ/(°) 99.9650(10) 90° 
V/Ǻ3 4768.03(19) 2850.04(17) 
Z, dcalcd /(g cm−3) 8, 1.207 4, 1.281 Mg/cm3 
µ/mm−1 0.077 0.084 
F(000) 1736 1148 
θ range/(°) 1.14 to 26.18 1.43 to 30.15° 
Index ranges −17<=h<=17 −17<=h<=15 
−22<=k<=22 −39<=k<=37 
−24<=l<=24 −10<=l<=11 
Reflections collected 70762 31805 
Independent 70762 31805 
Completeness 98.45% 97.6% 
Data/restraints/parameters 18968 / 0 / 1266 8228 / 0 / 381 
Goodness-of-fit onF2 0.848 0.683 
R1, wR2 [I>2σ(I)] 0.0471, 0.1492 R1 = 0.0564,wR2 
= 0.1203 
R1, wR2 (all data) 0.1545, 0.2418 R1 = 0.2088,wR2 
= 0.1506 
Largest diff. peak,hole/ 
(e A−3) 
0.234, −0.157 eÅ−3 d −0.238 
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SAR Study 
Several important structural features of coumarin 
and imidazole derivatives are identified and 
constructed as coumarin-imidazole skeleton. The 
various substituent’s on coumarin exhibits better 
antimicrobial activity as a result the SAR study was 
deduced by scrutinizing their results. 
 
Antibacterial Assay 
Imidazole nucleus at C-4 position of the coumarin 
conjugates 4a-m were screened for their antibacterial 
activity. The MIC results (Table IV) indicated that 
most of the compounds exhibited promising activity 
against both bacterial strains. Compounds 4a-g having 
N-1-phenyl substation on imidazole and different 
substitution on coumarin nucleus showed excellent 
antibacterial activity with MIC values 0.1 to 
0.4 µg/mL, except compound 4b (C7 methyl group 
substitution on coumarin nucleus) have not exhibited 
activity at a selected standard MIC values. Whereas, in 
the case of nitrobenzene substitution on N-1 imidazoles 
4h-m have exhibited higher activity at selected 
standard MIC. The structural modification on N-1 of 
imidazoles that is N-1-benzoic acid – imidazolo-
coumarins 6a-f was screened for their antibacterial 
activity. The results showed slight decrease in the 
antibacterial activity against both bacterial strains. 
Further, N-benzoic acid imidazolo-coumarin 
conjugates 6a-f were converted into corresponding 
methyl esters pharmacophores 7a-f. The results 
obtained are discussed in Table IV; it reveals the 
improvements in their active compared to compounds 
6a-f. Thus, the comparative evidence of the all series, 
compounds 7a-f showed promising antibacterial 
activity against Gram positive and Gram negative 
bacterial strains at low concentrations. The brief 
antibacterial study is drawn in Figure 3. 
 
Antifungal Assay 
All the synthesized compounds 4a-g, 4h-m, 6a-f 
and 7a-f were screened for their antifungal activity 
against Scopulariopsis spp. and Aspergillustereus 
organisms. The results obtained are summarized in 
Table IV, which indicates that all the compounds are 
excellent antifungal agents and the antifungal results 
are very similar to antibacterial activity results. The 
brief antifungal study is drawn in Figure 3. 
Imidazole -N-phenyl group with various 
substitutions on coumarin ring 4a-g. Introducing an 
electron withdrawing nitro group on para-position of 
N-1-phenyl ring and various substitutions on 
coumarin nucleus 4h-m and in the case of COOH and 
COOCH3 as electron withdrawing groups on N-1 of 
compounds 6a-f and 7a-f led to following 
antibacterial and antifungal structure activity 
relationship (SAR). 
The SAR study reveals that, in the series 4a-g, 
compounds 4b (R1 =CH3, R= H) N-1-phenyl 
substitution is found to be inactive, while introducing 
an electron withdrawing groups (EWGs) of the series 
4h-m, 6a-f and 7a-f: such as NO2 (4i), COOH (6b) 
and COOCH3 (7b) on N-1-phenyl ring at para-
position displayed promising antibacterial and fungal 
activity. This indicates that coumarin nucleus with C7 
substitution and EWGs on N-1-phenyl ring at para-
position is necessary. 
 
Table IV — In vitro anti-microbial activity of compounds 4a-g, 
4h-m, 6a-f and 7a-f 
Compd Minimum inhibitory concentration (MIC) in 
µg/mL 
Gram +ve Gram −ve Antifungal 
B. flexus P. Spp. S. spp. A. 
tereus 
4a 0.1 0.1 0.2 0.2 
4b − − − − 
4c 0.1 0.1 0.2 0.2 
4d 0.2 0.2 0.4 0.4 
4e 0.2 0.2 0.1 0.1 
4f 0.1 0.1 0.2 0.2 
4g 0.4 0.4 0.1 0.2 
4h − − − − 
4i 0.7 0.7 0.1 0.1 
4j 0.5 0.4 0.4 0.2 
4k 0.6 0.6 − − 
4l 0.5 0.5 0.3 0.3 
4m 0.2 0.2 0.3 0.3 
6a 0.4 0.4 0.1 0.2 
6b 0.2 0.1 0.4 0.4 
6c 0.1 0.1 − − 
6d − − − 0.2 
6e 0.4 0.4 0.1 0.2 
6f − − 0.2 0.2 
7a 0.2 0.2 03 02 
7b 0.1 0.1 0.1 0.2 
7c 0.2 0.1 0.2 0.2 
7d 0.2 0.1 0.2 0.2 
7e 0.2 0.1 0.1 0.2 
7f 0.2 0.1 0.2 0.1 
Ciprofloxacin 0.7 0.7 − − 
Nystatin − − 0.7 0.7 
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Docking Study 
The crystal structures used were Aspergillus 
fumigates N-myristoyltransferase in complex with 
myristoyl CoA and pyrazolesulphonamide ligand 
(PDB ID: 4CAW; A-Chain) and Candida albicans 
dihydrofolatereductase (PDB ID: 1AI9) was obtained 
from the Protein Data Bank. The proteins were 
prepared for docking by adding polar hydrogen atom 
with Gasteiger-Huckel charges and water molecules 
were removed. The 3D structure of the ligands was 
generated by the SKETCH module implemented in 
the SYBYL program (Tripos Inc., St. Louis, USA). 
The energy-minimized conformation was obtained 
with the help of the Tripos force field using 
Gasteiger-Huckel41 charges and molecular docking 
was performed with Surflex-Dock program that is 
interfaced with Sybyl-X 2.042 and other miscellaneous 
parameters were assigned with the default values 
given by the software. The molecular docking was 
performed on PDB 1AI9 and presented in the 
Figure 4, compound 4a, makes two hydrogen bonding 
interaction at the active site of the enzyme, oxygen 
atom of carbonyl group present at the 2nd position of 
the coumarin ring makes an hydrogen bonding 
interaction with hydrogen atom of the amino acid 
subunit TRP27 at the active site of the enzyme  
(C=O-----H-TRP27; 2.10 Å) and another interaction 
was raised from the oxygen atom of coumarin ring  
 
 
Figure 3 — Antibacterial and antifungal SAR study of coumarin-imidazole conjugates 
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with hydrogen atom of amino acid residue ALA11 
(O-----H-ALA11; 2.49 Å). As depicted in the 
Figure 5, compound 7f, makes two hydrogen  
bonding interaction at the active site of the enzyme 
(PDB ID: 1AI9), oxygen atom of the carbonyl group 
present at the 2nd position of the coumarin ring makes 
an hydrogen bonding interaction with hydrogen atom 
of the amino acid subunit GLU116 at the active site of 
 
 
Figure 4 — Docked view of compound 4a at the active site of the enzyme (PDB ID: 1AI9) 
 
 
 
Figure 5 — Docked view of compound 7f at the active site of the enzyme (PDB ID: 1AI9) 
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the enzyme (C=O-----H-GLU115; 2.00 Å) and another 
interaction was raised from the nitrogen atom of 
imidazoline ring with hydrogen atom of amino acid 
residue ALA115 (N-----H-ALA116; 2.36 Å). Whereas, 
molecular docking was performed on PDB 4CAW, as 
depicted in Figure 6, compound 7b makes an 
hydrogen bonding interaction with hydrogen atom of 
amino acid residue GLY455 at the active site of the 
enzyme (O-----H-GLY455; 2.05 Å). Docking score 
results are listed in Table V and Table VI 
respectively. It reveals that insilico docking studies 
supports the in vitro antibacterial study. 
 
Experimental Section 
Reagents were obtained from commercial sources 
and used without further purification until stated. 
Melting points were determined in open capillary tube 
on a Sheetal Scientific instrument, presented in degree 
centigrade and are incorrect. Infrared spectra were 
recorded on a Nicolet 410 Fourier transform (FT) 
infrared Spectrometer using KBr pellets. 1H and 
13C NMR spectra were recorded on Bruker 400 MHz 
instruments and further, chemical shifts are measured 
in terms of parts per million with TMS as the internal 
standard. 
 
 
 
Figure 6 — Docked view of compound 7b at the active site of the enzyme (PDB ID: 4CAW) 
 
Table V — Surflex docking score (kcal/mol) of the coumarin imidazole conjugates for Candida albicans (PDB ID: 1AI9) 
Compd C Scorea Crash Scoreb Polar Scorec D Scored PMF Scoree G Scoref ChemScoreg 
4a* 5.20 −1.88 0.86 −2057.47 8.16 −245.53 −45.56 
4b 3.89 −3.88 0.02 −1536.08 51.14 −252.74 −35.01 
4c 4.15 −0.79 0.13 −1874.35 14.26 −200.96 −35.82 
4d 5.13 −1.84 0.00 −1359.24 30.36 −243.26 −32.96 
4e 4.30 −0.79 0.81 −1710.17 11.53 −190.67 −39.89 
4f 4.99 −3.32 0.00 −1488.53 38.34 −248.64 −33.66 
4h 4.52 −1.32 0.69 −1794.80 23.71 −206.03 −40.31 
4i 3.21 −2.45 0.56 −1980.34 7.53 −227.30 −43.59 
4j 1.59 −9.88 2.87 −1542.95 28.74 −346.49 −50.19 
4k 2.96 −1.58 1.23 −1907.48 16.85 −206.32 −38.26 
4l 3.45 −0.53 0.82 −1771.01 −0.21 −198.24 −38.51 
4m 4.36 −2.64 0.02 −2045.28 23.41 −274.81 −49.49 
7a 2.42 −9.64 2.60 −1436.73 47.82 −366.82 −49.67 
(Contd.)
N
N O
O
O
O
H-GLY455
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Table V — Surflex docking score (kcal/mol) of the coumarin imidazole conjugates for Candida albicans (PDB ID: 1AI9) (Contd.) 
Compd C Scorea Crash Scoreb Polar Scorec D Scored PMF Scoree G Scoref ChemScoreg 
7b 3.24 −5.17 0.00 −1567.77 47.48 −272.38 −32.24 
7c 2.87 −5.05 0.00 −1599.11 45.12 −260.84 −31.86 
7d 0.79 −1.07 1.16 −702.33 −46.75 −108.22 −14.75 
7e 0.45 −11.80 0.12 −1092.36 18.13 −260.08 −26.75 
7f* 5.63 −0.75 1.24 −1778.78 27.50 −211.18 −38.53 
aC Score (Consensus Score) integrates a number of popular scoring functions for ranking the affinity of ligands bound to the active site of 
a receptor and reports the output of total score. 
b
 Crash-score revealing the inappropriate penetration into the binding site. Crash scores close to 0 are favorable. Negative numbers 
indicate penetration. 
c
 Polar indicating the contribution of the polar interactions to the total score. The polar score may be useful for excluding docking results 
that make no hydrogen bonds. 
d
 D-score for charge and van der Waals interactions between the protein and the ligand.  
e
 PMF-score indicating the Helmholtz free energies of interactions for protein-ligand atom pairs (Potential of Mean Force, PMF). 
f
 G-score showing hydrogen bonding, complex (ligand-protein), and internal (ligand-ligand) energies. 
gChem-score points for H-bonding, lipophilic contact, and rotational entropy, along with an intercept term. 
 
Table VI — Surflex docking scores (kcal/mol) of the coumarin imidazole conjugates for Aspergillus fumigates (PDB ID: 4CAW) 
Compd C Scorea Crash Scoreb Polar Scorec D Scored PMF Scoree G Scoref ChemScoreg 
4a 3.97 −1.86 0.00 −1801.92 −45.46 −225.26 −46.19 
4b 4.05 −1.41 −0.03 −1821.38 −65.78 −230.17 −46.47 
4c 5.01 −1.72 0.00 −1979.33 −72.70 −219.34 −44.99 
4d 4.57 −2.18 0.00 −1779.62 −29.45 −240.74 −46.46 
4e 4.60 −0.35 0.81 −1556.30 −33.51 −196.09 39.20 
4f* 5.11 −1.03 1.15 −1608.48 −54.02 −209.12 −46.28 
4h 3.52 −1.48 0.99 −1931.89 −105.37 −210.97 −45.94 
4i 3.67 −1.73 1.12 −1860.13 −83.76 −194.91 −48.51 
4j 4.95 −1.45 0.53 −2080.10 −50.69 −216.51 −42.22 
4k 4.87 −1.25 1.22 −1835.55 −94.96 −238.60 −47.73 
4l 2.13 −2.00 0.00 −1657.04 −11.86 −194.93 −36.63 
4m 4.64 −1.70 1.11 −1921.34 −108.76 −231.98 −51.12 
7a 4.90 −1.19 0.87 −1732.99 −87.83 −230.61 −45.56 
7b* 6.08 −1.20 1.13 −2007.77 −109.51 −235.32 −46.59 
7c 5.08 −1.43 1.18 −2069.57 −112.56 −225.30 −45.82 
7d 4.80 −1.24 0.94 −1868.53 −107.69 −210.90 −44.24 
7e 4.29 −1.47 2.02 −1716.87 −87.22 −227.26 −47.97 
7f* 5.23 −1.10 0.01 −1968.02 −90.04 −240.99 −42.10 
 
General procedure for synthesis of 4-(1,4,5-
triphenyl-1H-imidazol-2-yl)-2H-chromen-2-one 4a-
m, 6a-f 
 
Conventional Method 
Substituted 4-formylcoumarin 1 (0.00049 mol,  
100 mg) was added slowly into the reaction mixture 
of benzil 2 (0.00049 mol, 100 mg), ammonium 
acetate (0.00049 mol, 37 mg) and aniline/p-amino 
benzoic acid/p-nitro aniline (0.00049 mol) in acetic 
acid as a solvent (10 mL). The reaction mixture was 
stirred for 20 min at RT and heated at 90°C for 8 h, 
after completion (monitored by TLC) reaction was 
cooled to RT and quenched with ice water, the 
residues obtained was extracted with ethyl acetate. 
The organic phase was washed with water and dried 
over anhydrous Na2SO4. After concentration the crude 
product was purified by column chromatography 
(hexane: ethyl acetate) to obtain the desired product 
4a-m, 6a-f. 
 
Microwave Method 
Substituted 4-formylcoumarin 1 (0.00049 mol,  
100 mg) was added slowly into the reaction mixture 
of benzil 2 (0.00049 mol, 100 mg), ammonium 
acetate (0.00049 mol, 37 mg) and aniline/p-amino 
benzoic acid/p-nitro aniline (0.00049 mol) in acetic 
acid as a solvent (2 mL). The reaction mixture was 
stirred for 20 min at RT and heated at 100°C for  
5 min, after completion (monitored by TLC) reaction 
was cooled to RT and quenched with ice water, the 
residues obtained was extracted with ethyl acetate. 
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The organic phase was washed with water and dried 
over anhydrous Na2SO4. After concentration the crude 
product was purified by column chromatography 
(hexane:ethyl acetate) to obtain the desired product 
4a-m, 6a-f. 
6-Methyl-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-2H-
chromen-2-one 4a: White solid. Yield 86%. m.p.210-
212°C. IR (KBr): 1728 cm−1; 1H NMR (400 MHz, 
DMSO-d6): δ 7.92 (d, J = 1.2 Hz, 1H), 7.51 (dd,  
J = 1.2 & 5.2 Hz, 2H), 7.44 (dd, J = 2 Hz, 1H), 7.29 
(m, 14H), 6.21 (s, 1H), 2.34 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 159.08 (C2 of coumarin), 151.48 
(C4 of coumarin), 142.93 (C9 of coumarin), 140.39 
(C2 of imidazole), 137.80 (C6 of coumarin), 135.48 
(Ar-C), 133.75 (Ar-C), 133.66 (Ar-C), 133.22 (Ar-C), 
132.19 (C4 of imidazole), 131.55 (Ar-C), 130.97 (Ar-C), 
129.64 (Ar-C), 129.01 (Ar-C), 128.89 (Ar-C), 128.73 
(C7 of coumarin), 128.53 (Ar-C), 128.29 (Ar-C), 
128.15 (Ar-C), 127.87 (C5 of coumarin), 127.48  
(Ar-C), 126.86 (C5 of imidazole), 126.41 (Ar-C), 
126.11 (Ar-C), 122.43 (C8 of coumarin ), 121.65 (C10 
of coumarin) 121.21 (Ar-C) 120.35 (Ar-C), 119.19 
(Ar-C), 119.39 (C3 of coumarin), 20.41 (CH3 of 
coumarin); GC-MS: m/z Calcd for C31H22N2O5: 
454.17. Found: 454. 
7-Methyl-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-
2H-chromen-2-one 4b: White solid. Yield 86%. 
m.p.205-207°C. IR (KBr): 1728 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 7.92 (d, J = 1.2 Hz, 1H), 7.51 (d, 
J = 7.2 Hz, 2H), 7.44 (dd, J = 8.4 Hz, 1H), 7.27 (m, 
22), 6.215 (s, 1H), 2.34 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 159.08 (C2 of coumarin), 151.48 (C4 of 
coumarin), 142.93 (C9 of coumarin), 140.39 (C2 of 
imidazole), 137.80 (C6 of coumarin), 135.48 (Ar-C), 
133.75 (Ar-C), 133.66 (Ar-C), 133.22 (Ar-C), 132.19 
(C4 of imidazole), 130.97 (Ar-C), 127.79 (Ar-C ), 
129.64 (Ar-C), 129.33 (Ar-C), 129.01 (Ar-C), 128.89 
(Ar-C), 128.73 (C7 of coumarin), 128.53 (Ar-C), 
128.29 (Ar-C), 128.15 (Ar-C), 127.48 (C5 of 
coumarin),127.54 (Ar-C ), 126.41 (C5 of imidazole), 
122.21 (Ar-C), 121.56 (Ar-C), 121.22 (C10 of 
coumarin), 120.35 (Ar-C), 117.35 (C8 of coumarin), 
117.19 (Ar-C), 116.39 (C3 of coumarin) 20.41(CH3 of 
coumarin); GC-MS: m/z Calcd for C31H22N2O5 
454.17. Found: 454. 
6-Methoxy-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-
2H-chromen-2-one 4c: White solid. Yield 78%. 
m.p.212-214°C. IR (KBr): 1730 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 7.94 (d, J = 1.2 Hz, 1H), 7.54 
(dd, J = 1.2 & 5.2 Hz, 2H), 7.38 (dd, J = 2 Hz, 1H), 
7.30 (m, 14H), 6.18 (s, 1H), 3.84 (s, 3H); 13C NMR 
(100 MHz, DMSO-d6): δ 159.00 (C2 of coumarin), 
151.55 (C4 of coumarin), 142.94 (C9 of coumarin), 
140.38 (C2 of imidazole), 137.82 (C6 of coumarin), 
135.41 (Ar-C), 133.76 (Ar-C), 133.68 (Ar-C), 133.19 
(Ar-C), 132.18 (C4 of imidazole), 130.96 (Ar-C), 
129.66 (Ar-C), 129.00 (Ar-C), 128.84 (Ar-C), 128.74 
(C7 of coumarin), 128.58 (Ar-C), 128.32 (Ar-C), 
128.16 (Ar-C), 127.92 (Ar-C), 127.73 (Ar-C), 127.52 
(C5 of coumarin), 126.87 (Ar-C), 126.42 (C10 of 
coumarin), 124.21 (Ar-C), 123.68 (C5 of imidazole ), 
122.45 (Ar-C), 120.87 (Ar-C) 120.33 (C8 of 
coumarin), 119.19 (Ar-C), 118.39 (C3 of coumarin), 
52.04 (OCH3 of coumarin); GC-MS: m/z Calcd for 
C31H22N2O3:470.52. Found: 470. 
6-Bromo-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-2H-
chromen-2-one 4d: White solid. Yield 80%. 
m.p.214-216°C. IR (KBr): 1718 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 7.94 (d, J = 1.2 Hz, 1H), 7.52 
(dd, J = 1.2 & 5.2 Hz, 2H), 7.38 (dd, J = 2 Hz, 1H), 
7.30 (m, 14H), 6.22 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6): δ 159.00 (C2 of coumarin), 151.49 (C4 of 
coumarin), 142.91 (C9 of coumarin), 140.33 (C2 of 
imidazole), 137.78 (C6 of coumarin), 135.49 (Ar-C), 
133.76 (Ar-C), 133.68 (Ar-C), 133.24 (Ar-C), 132.20 
(C4 of imidazole), 130.98 (Ar-C), 129.78 (Ar-C), 
129.51 (Ar-C), 129.21 (Ar-C), 128.83 (Ar-C), 128.74 
(C7 of coumarin), 128.55 (Ar-C), 128.30 (Ar-C), 
128.16 (Ar-C), 127.52 (C5 of coumarin), 127.42  
(Ar-C), 126.82 (Ar-C), 126.40 (C5 of imidazole), 
122.33 (Ar-C), 121.48 (Ar-C), 121.35 (Ar-C), 121.02 
(C8 of coumarin ), 120.34 (C10of coumarin), 119.90 
(Ar-C), 119.40 (C3 of coumarin); GC-MS: m/z Calcd 
for C30H19BrN2O2:519.39. Found: 519. 
6-Chloro-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-2H-
chromen-2-one 4e: White solid. Yield 74%. m.p.218-
220°C. IR (KBr): 1720 cm−1; 1H NMR (400 MHz, 
DMSO-d6): δ 7.98 (d, J = 1.2 Hz, 1H), 7.54 (dd,  
J = 1.2 & 5.2 Hz, 2H), 7.41 (dd, J = 2 Hz, 1H), 7.27 
(m, 14H), 6.16 (s, 1H); 13C NMR (100 MHz, DMSO-d6): 
δ 159.08 (C2 of coumarin), 151.38 (C4 of coumarin), 
142.92 (C9 of coumarin), 140.34 (C2 of imidazole), 
137.82 (C6 of coumarin), 135.46 (Ar-C), 133.72  
(Ar-C), 133.56 (Ar-C), 133.22 (Ar-C), 132.21 (C4 of 
imidazole), 130.86 (Ar-C), 130.00 (Ar-C), 129.02 
(Ar-C), 128.88 (Ar-C), 128.62 (C7 of coumarin), 
128.52 (Ar-C), 128.28 (Ar-C), 128.11 (Ar-C), 128.88 
(Ar-C), 127.92 (Ar-C), 127.36 (C5 of coumarin), 
126.80 (Ar-C), 126.42 (C5 of imidazole), 122.73 (C10 
of coumarin) 122.21 (Ar-C), 121.56 (Ar-C), 120.35 
(Ar-C), 118.33 (C8 of coumarin), 117.16 (Ar-C), 
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116.42 (C3 of coumarin); GC-MS: m/z Calcd for 
C30H19ClN2O2:474.94. Found: 474. 
4-(1,4,5-triphenyl-1H-imidazol-2-yl)-2H-benzo[h] 
chromen-2-one 4f: White solid. Yield 75%. m.p.220-
218°C. IR (KBr): 1725 cm−1; 1H NMR (400 MHz, 
DMSO-d6): δ 7.96 (d, J = 1.2 Hz, 1H), 7.52 (dd, J = 1.2 
& 5.2 Hz, 3H), 7.44 (dd, J = 2 Hz, 3H), 7.28 (m, 14H), 
6.16 (s, 1H); 13C NMR (100 MHz, DMSO-d6):  
δ 159.00 (C2 of coumarin), 151.38 (C4 of coumarin), 
142.94 (C9 of coumarin), 140.34 (C2 of imidazole), 
137.82 (C6 of coumarin), 135.46 (Ar-C), 133.72  
(Ar-C), 133.56 (Ar-C), 133.22 (Ar-C), 132.21 (C4 of 
imidazole), 130.86 (Ar-C), 130.60 (Ar-C), 130.54 
(Ar-C) 129.84 (Ar-C), 129.34 (Ar-C), 129.22 (Ar-C), 
129.09 (Ar-C), 128.88 (C7 of coumarin), 128.59  
(Ar-C), 128.50 (Ar-C), 128.31 (Ar-C), 128.21 (Ar-C), 
127.74 (C14 of coumarin), 127.54 (C11 of coumarin), 
127.13 (C12 of coumarin), 126.78 (C5 of coumarin), 
126.41 (C5 of imidazole), 125.83 (C8 of coumarin), 
124.52 (C13 of coumarin ), 122.98 (Ar-C), 122.13 
 (Ar-C), 121.85 (Ar-C), 121.03 (C10 of coumarin), 
118.45 (C3 of coumarin); GC-MS: m/z Calcd for 
C34H21N2O2:490.55. Found: 490. 
5,7-Dimethyl-4-(1,4,5-triphenyl-1H-imidazol-2-yl)-
2H-chromen-2-one 4g: White solid. Yield 92%, mp: 
210-212°C. IR (KBr): 1706 cm−1; 1H NMR (400 
MHz, DMSO-d6): δ 7.48 (d, J = 8 Hz, 1H), 7.32 (d,  
J = 4 Hz, 2H), 7.27 (m, 7H), 7.08 (d, J = 4 Hz, 2H), 
6.97 (3H, m), 6.64 (s, 1H), 6.43 (s, 1H), 6.31 (s, 1H), 
2.33 (s. 6H); 13C NMR (100 MHz, DMSO-d6):  
δ 159.37 (C2 of coumarin), 152.42 (C4 of coumarin), 
142.94 (C9 of coumarin), 141.83 (C2 of imidazole), 
136.49 (C6 of coumarin), 135.00 (Ar-C), 133.90  
(Ar-C), 133.45 (Ar-C), 132.25 (Ar-C), 131.03 (C4 of 
imidazole), 129.72 (Ar-C), 129.16 (Ar-C), 128.76 
(Ar-C), 128.37 (Ar-C), 128.12 (Ar-C), 127.98 (C7 of 
coumarin), 127.28 (Ar-C), 127.12 (Ar-C), 126.89  
(Ar-C), 126.35 (C5 of coumarin), 125.88 (Ar-C), 
125.03 (C5 of imidazole), 122.95 (Ar-C), 122.11 (C10 
of coumarin), 121.44 (Ar-C), 120.35 (Ar-C), 119.71 
(Ar-C), 119.42 (C8 of coumarin), 118.80 (Ar-C), 
118.37 (C3 of coumarin), 23.19 (CH3 of coumarin), 
20.62 (CH3 of coumarin); GC-MS: m/z Calcd for 
C31H22N2O5:468.18. Found: 468. 
4-(2-(6-Methoxy-2-oxo-2H-chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoic acid 4h: White 
solid. Yield 88%. m.p.196-198°C. IR (KBr) 1728 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.94 (s, 
1H), 8.40 (s, 1H), 8.12 (d, J = 8 Hz, 2H), 7.85 (d,  
J = 8 Hz, 3H), 7.44 (s, 1H), 7.38 (d, J = 4 Hz, 1H), 
7.32 (d, J = 4 Hz, 2H), 7.24 (m, 6H), 7.28 (d,  
J = 8 Hz, 1H), 7.10 (s, 1H), 2.34 (s, 3H); 13C NMR 
(100 MHz, DMSO-d6): δ 194.02 (C of COOH), 
168.12 (C2 of coumarin), 166.76 (C4 of coumarin), 
159.64 (C9 of coumarin), 156.01 (C2 of imidazole), 
153.64 (C6 of coumarin), 148.38 (Ar-C), 142.44 (Ar-
C), 140.58 (Ar-C), 138.42 (Ar-C), 134.02 (C4 of 
imidazole), 133.84 (Ar-C), 132.52 (Ar-C), 131.67 
(Ar-C), 131.55 (Ar-C), 130.23 (C7 of coumarin), 
129.20 (Ar-C), 128.91 (Ar-C), 128.44 (Ar-C), 127.44 
(Ar-C), 126.88 (Ar-C), 126.71 (C5 of coumarin), 
126.43 (Ar-C)), 125.21 (C5 of imidazole), 125.10 (Ar-C), 
124.82 (Ar-C), 122.18 (Ar-C), 121.28 (C8 of 
coumarin), 120.13 (C10 of coumarin), 120.06 (Ar-C), 
118.00 (C3 of coumarin), 20.27 (CH3 of coumarin),. 
4-(2-(7-Methyl-2-oxo-2H-chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoic acid 4i: White 
solid. Yield 90%. m.p.198-200°C. IR (KBr) 1725 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.96  
(s, 1H), 8.42 (s, 1H), 8.10 (d, J = 8 Hz, 2H), 7.84 (d,  
J = 8 Hz, 3H), 7.44 (s, 1H), 7.36 (d, J = 4 Hz, 1H), 
7.31 (d, J = 4 Hz, 2H), 7.25 (m, 6H), 7.30 (d, J = 8 Hz, 
1H), 7.12 (s, 1H), 2.35 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 194.00 (C of COOH), 168.14 (C2 of 
coumarin), 166.77 (C4 of coumarin), 159.65 (C9 of 
coumarin), 156.02 (C2 of imidazole), 153.60 (C6 of 
coumarin), 148.40 (Ar-C), 142.45 (Ar-C), 140.56  
(Ar-C), 134.00 (Ar-C), 132.85 (C4 of imidazole), 
131.94 (Ar-C), 131.64 (Ar-C), 130.66 (Ar-C), 129.82 
(Ar-C), 129.62 (Ar-C), 129.32 (Ar-C), 128.92 (C7 of 
coumarin), 128.80 (Ar-C), 128.31 (Ar-C), 127.72  
(Ar-C), 127.69 (Ar-C), 127.48 (Ar-C), 127.23 (Ar-C), 
126.96 (C5 of coumarin), 126.68 (Ar-C), 126.45  
(Ar-C), 122.82 (C8 of coumarin), 122.23 (C5 of 
imidazole), 120.21 (C10 of coumarin), 118.26 (C3 of 
coumarin), 20.25 (CH3 of coumarin). 
4-(2-(6-Methoxy-2-oxo-2H-chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoicacid 4j: White 
solid. Yield 82%, mp198-200°C. IR (KBr) 1718 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.96 (s, 
1H), 8.41 (s, 1H), 8.05 (d, J = 8 Hz, 1H), 7.84 (d,  
J = 8 Hz, 2H), 7.45 (s, 1H), 7.43 (d, J = 4 Hz, 2H), 
7.36 (d, J = 4 Hz, 2H), 7.31 (m, 6H), 7.29 (d, J = 8 
Hz, 2H), 7.01 (s, 1H), 3.81 (s, 3H); 13C NMR  
(100 MHz, DMSO-d6): δ 194.08 (C of COOH), 
168.00 (C2 of coumarin), 166.81 (C4 of coumarin), 
159.63 (C9 of coumarin), 155.98 (C2 of imidazole), 
153.63 (C6 of coumarin), 148.36 (Ar-C), 142.42  
(Ar-C), 140.66 (Ar-C), 134.05 (Ar-C), 132.85 (C4 of 
imidazole), 131.71 (Ar-C), 130.65 (Ar-C), 130.32 
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(Ar-C), 129.72 (Ar-C), 129.21 (Ar-C), 128.92 (Ar-C), 
128.15 (C7 of coumarin), 127.92 (Ar-C), 127.78 (C5 
of coumarin), 127.56 (Ar-C), 127.22 (Ar-C), 126.86 
(Ar-C), 126.57 (Ar-C), 126.27 (Ar-C), 126.12 (Ar-C), 
125.92 (Ar-C), 122.37 (C5 of imidazole), 121.93 (C8 
of coumarin), 121.56 (C10 of coumarin), 119.82 (C3 of 
coumarin), 56.27 (OCH3 of coumarin). 
4-(2-(6-Bromo-2-oxo-2H-chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoic acid 4k: White 
solid. Yield 78%. m.p.194-196°C. IR (KBr) 1700 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.95 (s, 
1H), 8.42 (s, 1H), 8.14 (d, J = 8 Hz, 2H), 7.86 (d,  
J = 8 Hz, 3H), 7.40 (s, 1H), 7.41 (d, J = 4 Hz, 1H), 
7.34 (d, J = 4 Hz, 2H), 7.22 (m, 6H), 7.28 (d,  
J = 8 Hz, 1H), 7.10 (s, 1H); 13C NMR (100 MHz, 
DMSO-d6): δ 194.21 (C of COOH), 168.32 (C2 of 
coumarin), 166.77 (C4 of coumarin), 159.64 (C9 of 
coumarin), 156.00 (C2 of imidazole), 153.65 (C6 of 
coumarin), 148.41 (Ar-C), 142.46 (Ar-C), 140.60  
(Ar-C), 134.00 (Ar-C), 132.85 (C4 of imidazole), 
131.72 (Ar-C), 130.66 (Ar-C), 130.12 (Ar-C), 129.65 
(Ar-C), 129.47 (Ar-C), 129.23 (Ar-C), 128.89 (Ar-C), 
128.67 (Ar-C), 128.51 (Ar-C), 128.28 (Ar-C), 127.75 
(C5 of coumarin), 127.36 (Ar-C), 126.86 (C7 of 
coumarin), 126.12 (Ar-C), 124.55 (C5 of imidazole), 
122.89 (Ar-C), 122.02 (C8 of coumarin), 121.56 (Ar-C), 
120.12 (C10 of coumarin), 119.84 (C3 of coumarin). 
4-(2-(6-Chloro-2-oxo-2H-chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoic acid 4l: White 
solid,yield 74%. m.p.196-198°C. IR (KBr) 1702 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.96 (s, 
1H), 8.41 (s, 1H), 8.12 (d, J = 8 Hz, 2H), 7.84 (d,  
J = 8 Hz, 3H), 7.42 (s, 1H), 7.40 (d, J = 4 Hz, 1H), 
7.32 (d, J = 4 Hz, 2H), 7.20 (m, 6H), 7.18 (d, J = 8 Hz, 
1H), 7.12 (s, 1H); 13C NMR (100 MHz, DMSO-d6):  
δ 194.22 (C of COOH), 168.34 (C2 of coumarin), 
166.76 (C4 of coumarin), 159.65 (C9 of coumarin), 
156.04 (C2 of imidazole), 153.68 (C6 of coumarin), 
148.42 (Ar-C), 142.45 (Ar-C), 140.62 (Ar-C), 134.02 
(C4 of imidazole), 132.86 (Ar-C), 131.74 (Ar-C), 
130.68 (Ar-C), 129.86 (Ar-C), 129.59 (Ar-C), 129.22 
(Ar-C), 128.91 (Ar-C), 128.76 (Ar-C), 128.42 (Ar-C), 
127.89 (C7 of coumarin), 127.54 (C5 of coumarin), 
127.21 (Ar-C), 126.67 (Ar-C), 124.14(Ar-C), 123.33 
(C8 of coumarin). 122.56 (C5 of imidazole), 121.89 
(Ar-C), 121.14 (C10 of coumarin), 120.82 (Ar-C), 
120.22 (Ar-C), 118.30 (C3 of coumarin). 
4-(2-(2-Oxo-2H-benzo[h]chromen-4-yl)-4,5-
diphenyl-1H-imidazol-1-yl)benzoic acid 4m: White 
solid. Yield 90%. m.p.200-202°C. IR (KBr) 1730 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 8.95  
(s, 1H), 8.42 (s, 1H), 8.14 (d, J = 8 Hz, 2H), 7.84 (d,  
J = 8 Hz, 4H), 7.42 (s, 1H), 7.36 (d, J = 4 Hz, 1H), 
7.34 (d, J = 4 Hz, 4H), 7.25 (m, 6H), 7.28 (d, J = 8 Hz, 
1H), 7.12 (s, 1H); 13C NMR (100 MHz, DMSO-d6):  
δ 194.12 (C of COOH), 168.14 (C2 of coumarin), 
159.66 (C4 of coumarin), 156.00 (C13 of coumarin), 
153.62 (Ar-C), 148.41 (C2 of imidazole), 142.69 (C12 
of coumarin), 140.62 (Ar-C), 141.58 (Ar-C), 134.00 
(C4 of imidazole), 132.82 (Ar-C), 131.70 (Ar-C), 
130.64 (Ar-C), 129.22 (Ar-C), 128.92 (Ar-C), 126.86 
(Ar-C), 125.40 (Ar-C),124.23 (Ar-C), 123.59 (Ar-C), 
120.12 (Ar-C), 120.04 (Ar-C), 119.86 (Ar-C), 119.20 
(Ar-C), 118.27 (Ar-C), 113.15 (Ar-C), 110.07 (C8 of 
coumarin), 109.02 (C9 of coumarin), 108.74 (C5 of 
imidazole), 108.66 (C5 of coumarin), 108.40 (Ar-C), 
108.28 (Ar-C), 107.44 (C6 of coumarin), 107.31 (C10 
of coumarin), 106.82 (C3 of coumarin), 105.70 (C14 of 
coumarin). 
6-Methyl-4-(1-(4-nitrophenyl)-4,5-diphenyl-1H-
imidazol-2-yl)-2H-chromen-2-one 6a: White solid. 
Yield 92%. m.p.232-234°C. IR (KBr) 1719 νmaxcm−1; 
1H NMR (400 MHz, DMSO-d6): δ 9.25 (s, 1H), 8.25 
(d, J = 8 Hz, 2H), 8.00 (d, J = 8 Hz, 2H), 7.80 (m, 
4H), 7.68 (m, 2H), 7.40 (m, 2H), 7.20 (m, 3H), 7.00 
(m, 1H), 6.40 (s, 1H), 2.40 (s, 3H); 13C NMR  
(100 MHz, DMSO-d6): δ 160.64 (C2 of coumarin), 
159.50 (C4 of coumarin), 156.10 (C9 of coumarin), 
155.23 (Ar-C), 152.12 (Ar-C), 147.21 (C2 of 
imidazole), 144.76 (C6 of coumarin), 143.71 (Ar-C), 
142.94 (Ar-C), 142.36 (C4 of imidazole), 140.77 (Ar-C), 
139.46 (Ar-C), 136.12 (Ar-C), 133.16 (Ar-C), 131.02 
(C7 of coumarin), 130.37 (Ar-C), 130.22 (Ar-C), 
129.97 (Ar-C), 129.29 (Ar-C), 129.14 (Ar-C), 128.56 
(Ar-C), 128.02 (C5 of imidazole), 127.68 (Ar-C), 
127.41 (Ar-C), 124.86 (Ar-C), 119.76 (C8 of 
coumarin), 116.61 (C10 of coumarin), 116.33 (C3 of 
coumarin), 115.36 (Ar-C), 115.14 (C5 of coumarin), 
24.12 (CH3 of coumarin). 
7-Methyl-4-(1-(4-nitrophenyl)-4,5-diphenyl-1H-
imidazol-2-yl)-2H-chromen-2-one 6b: White solid. 
Yield 90%. m.p.234-236°C. IR (KBr) 1720 νmaxcm−1; 
1H NMR (400 MHz, DMSO-d6): δ 9.26 (s, 1H), 8.24 
(d, J = 8 Hz, 2H), 8.04 (d, J = 8 Hz, 2H), 7.82 (m, 
4H), 7.70 (m, 2H), 7.42 (m, 2H), 7.22 (m, 3H), 7.02 
(m, 1H), 6.42 (s, 1H), 2.44 (s, 3H); 13C NMR (100 
MHz, DMSO-d6): δ 160.62 (C2 of coumarin), 159.50 
(C4 of coumarin), 156.12 (C9 of coumarin), 155.24 
(Ar-C), 152.10 (Ar-C), 147.22 (C2 of imidazole), 
144.78 (C6 of coumarin), 143.72 (Ar-C), 142.95 (Ar-C), 
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142.38 (C4 of imidazole), 140.78 (Ar-C), 139.48  
(Ar-C), 136.14 (Ar-C), 133.18 (Ar-C), 131.00 (C7 of 
coumarin), 130.38 (Ar-C), 130.24 (Ar-C), 129.98  
(Ar-C), 129.31 (Ar-C), 129.15(Ar-C), 128.58 (Ar-C), 
128.00 (C5 of imidazole), 127.72 (Ar-C), 124.88  
(Ar-C), 124.55 (Ar-C), 119.78 (C8 of coumarin), 116.62 
(C10 of coumarin), 116.34 (C3 of coumarin), 115.34  
(Ar-C), 115.15 (Ar-C), 24.14 (CH3 of coumarin). 
6-Methoxy-4-(1-(4-nitrophenyl)-4,5-diphenyl-
1H-imidazol-2-yl)-2H-chromen-2-one 6c: White 
solid. Yield 88%. m.p.234-236°C. IR (KBr) 1718 
νmaxcm
−1; 1H NMR (400 MHz, DMSO-d6): δ 9.26 (s, 
1H), 8.24 (d, J = 8 Hz, 2H), 8.04 (d, J = 8 Hz, 2H), 
7.82 (m, 4H), 7.70 (m, 2H), 7.42 (m, 2H), 7.22 (m, 
3H), 7.08 (m, 1H), 6.42 (s, 1H), 3.86 (s, 3H); 
13C NMR (100 MHz, DMSO-d6): δ 160.65 (C2 of 
coumarin), 159.52 (C4 of coumarin), 156.14 (C9 of 
coumarin), 155.24 (Ar-C), 152.11 (Ar-C), 147.20 (C2 
of imidazole), 144.78 (C6 of coumarin), 143.72  
(Ar-C), 142.96 (Ar-C), 142.38 (C4 of imidazole), 
140.68 (Ar-C), 139.48 (Ar-C), 136.14 (Ar-C), 133.18 
(Ar-C), 131.04 (C7 of coumarin), 130.38 (Ar-C), 
130.24 (Ar-C), 129.98 (Ar-C), 129.30 (Ar-C), 129.15 
(Ar-C), 128.58 (Ar-C), 128.04 (C5 of imidazole), 
127.69 (Ar-C), 127.42 (Ar-C), 124.78 (Ar-C), 119.72 
(Ar-C), 116.62 (C8 of coumarin), 116.34 (C10 of 
coumarin), 115.38 (C3 of coumarin), 115.16 (Ar-C), 
51.24 (OCH3 of coumarin). 
6-Bromo-4-(1-(4-nitrophenyl)-4,5-diphenyl-1H-
imidazol-2-yl)-2H-chromen-2-one 6d: White solid. 
Yield 80%. m.p.230-232°C. IR (KBr) 1730 νmaxcm−1; 
1H NMR (400 MHz, DMSO-d6): δ 9.24 (s, 1H), 8.27 
(d, J = 8 Hz, 2H), 8.08 (d, J = 8 Hz, 2H), 7.84 (m, 
4H), 7.66 (m, 2H), 7.42 (m, 2H), 7.22 (m, 3H), 7.04 
(m, 1H), 6.42 (s, 1H); 13C NMR (100 MHz, DMSO-
d6): δ 160.66 (C2 of coumarin), 159.52 (C4 of 
coumarin), 156.12 (C9 of coumarin), 155.20 (Ar-C), 
152.11 (Ar-C), 147.22 (C2 of imidazole), 144.68  
(C6 of coumarin), 143.70 (Ar-C), 142.92 (Ar-C), 
142.35 (C4 of imidazole), 140.79 (Ar-C), 139.47  
(Ar-C), 136.13 (Ar-C), 133.11 (Ar-C), 131.00 (C7 of 
coumarin), 130.38 (Ar-C), 130.24 (Ar-C), 129.98  
(Ar-C), 129.30 (Ar-C), 129.15 (Ar-C), 128.58 (Ar-C), 
128.00 (C5 of imidazole), 127.69 (Ar-C), 127.42  
(Ar-C), 124.88 (Ar-C), 119.77 (Ar-C), 116.62 (C8 of 
coumarin), 116.30 (C10 of coumarin), 115.34 (C3 of 
coumarin), 115.00 (Ar-C). 
6-Chloro-4-(1-(4-nitrophenyl)-4,5-diphenyl-1H-
imidazol-2-yl)-2H-chromen-2-one 6e: White solid. 
Yield 78%. m.p.232-234°C. IR (KBr) 1732 νmaxcm−1; 
1H NMR (400 MHz, DMSO-d6): δ 9.26 (s, 1H), 8.26 
(d, J = 8 Hz, 2H), 8.06 (d, J = 8 Hz, 2H), 7.86 (m, 
4H), 7.66 (m, 2H), 7.44 (m, 2H), 7.20 (m, 3H), 7.06 
(m, 1H), 6.45 (s, 1H); 13C NMR (100 MHz, DMSO-d6): 
δ 160.64 (C2 of coumarin), 159.54 (C4 of coumarin), 
156.14 (C9 of coumarin), 155.22 (Ar-C), 152.12  
(Ar-C), 147.24 (C2 of imidazole), 144.70 (C6 of 
coumarin), 143.72 (Ar-C), 142.94 (Ar-C), 142.36 (C4 
of imidazole), 140.80 (Ar-C), 139.48 (Ar-C), 136.14 
(Ar-C), 133.12 (Ar-C), 131.04 (Ar-C), 130.40 (Ar-C), 
130.25 (C5 of imidazole), 129.99 (Ar-C), 129.32  
(Ar-C), 129.16 (Ar-C), 128.60 (Ar-C), 127.78 (Ar-C), 
126.64 (Ar-C), 126.32 (Ar-C), 125.35 (Ar-C), 125.04 
(Ar-C) 124.04 (C8 of coumarin), 123.70 (C10 of 
coumarin), 122.44 (C3 of coumarin), 121.89 (Ar-C). 
4-(1-(4-Nitrophenyl)-4,5-diphenyl-1H-imidazol-
2-yl)-2H-benzo[h]chromen-2-one 6f: White solid. 
Yield 88%. m.p.230-232°C. IR (KBr) 1720 νmaxcm−1; 
1H NMR (400 MHz, DMSO-d6): δ 9.24 (s, 1H), 8.26 
(d, J = 8 Hz, 2H), 8.04 (d, J = 8 Hz, 3H), 7.80 (m, 
4H), 7.72 (m, 4H), 7.42 (m, 2H), 7.21 (m, 3H), 7.02 
(m, 1H), 6.44 (s, 1H); 13C NMR (100 MHz, DMSO-d6): 
δ 160.65 (C2 of coumarin), 159.52 (C4 of coumarin), 
156.12 (C13 of coumarin), 155.24 (Ar-C), 152.14  
(Ar-C), 147.22 (C2 of imidazole), 144.74 (C12 of 
coumarin), 143.72 (Ar-C), 142.95 (Ar-C), 142.38 (C4 
of imidazole), 140.76 (Ar-C), 139.48 (Ar-C), 136.14 
(Ar-C), 133.18 (Ar-C), 131.04 (Ar-C), 130.38 (Ar-C), 
130.24 (Ar-C), 129.95 (Ar-C), 129.30 (Ar-C), 129.15 
(Ar-C), 128.58 (C7 of coumarin), 128.00 (C8 of 
coumarin), 127.72 (C9 of coumarin), 127.42 (C11 of 
coumarin), 124.88 (C5 of imidazole), 119.78 (Ar-C), 
116.62 (Ar-C), 116.34 (Ar-C), 115.35 (Ar-C), 115.12 
(C10 of coumarin)114.86 (C5 of coumarin), 113.22 (C6 
of coumarin), 112.46 (C3 of coumarin), 112.31 (C12 of 
coumarin). 
General procedure for synthesis of methyl 4-(2-
(2-oxo-2H-chromen-4-yl)-4,5-diphenyl-1H-imidazol-
1-yl) benzoate 7a-f 
Compound 4a (0.00018 mol, 0.1 gm) was 
dissolved in 20 mL of dry methanol together with 
con. H2SO4 (5 mL) was added to the cold solution, the 
mixture was brought to reflux at 80°C for 4 h. After 
completion (monitored by TLC), the resulting mixture 
was poured into ice cold water and stirred for 10 min, 
filtered and washed with water thoroughly to obtain 
white solid product. 
Methyl-4-(2-(6-methyl-2-oxo-2H-chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7a: White 
solid. Yield 89%. m.p.189-191°C. IR (KBr): 1708, 
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1672 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.42 (s, 
1H), 8.03 (d, J = 8 Hz, 1H), 7.83 (d, J = 8.8 Hz, 2H), 
7.44 (d, J = 8 Hz, 2H), 7.36 (d, J = 8 Hz, 2H), 7.32 
(m, 6H), 7.33 (d, J = 8 Hz, 1H), 7.28 (s, 1H), 6.77 (d, 
J = 12 Hz, 1H), 6.52 (d, J = 8 Hz, 1H), 4.18 (s, 3H), 
2.32 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 
174.91 (C of ester carbonyl), 160.15 (C2 of coumarin), 
153.99 (C9 of coumarin), 142.78 (C7 of coumarin), 
140.99 (C2 of imidazole), 140.20 (Ar-C), 138.92  
(Ar-C), 134.28 (C4 of imidazole), 130.31 (Ar-C), 
129.91 (Ar-C), 128.69 (Ar-C), 128.60 (Ar-C), 128.43 
(Ar-C), 128.36 (C5 of imidazole), 127.20 (Ar-C), 
127.09 (Ar-C), 125.95 (Ar-C), 125.45 (C5 of 
coumarin), 124.29 (C6of coumarin), 116.70 (Ar-C), 
114.11 (Ar-C), 113.39 (C8 of coumarin), 111.43 (C3 
of coumarin), 110.81 (C10 of coumarin), 58.96 (CH3 
of ester), 20.97 (CH3 of coumarin). 
Methyl-4-(2-(7-methyl-2-oxo-2H-chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7b: White 
solid. Yield 85%. m.p.190-192°C. IR (KBr): 1700, 
1668 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.40 (s, 
1H), 8.04 (d, J = 8 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 
7.44 (d, J = 8 Hz, 2H), 7.30 (d, J = 8 Hz, 2H), 7.36 
(m, 6H), 7.33 (d, J = 8 Hz, 1H), 7.26 (s, 1H), 6.78 (d, 
J = 12 Hz, 1H), 6.50 (d, J = 8 Hz, 1H), 4.20 (s, 3H), 
2.32 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 
174.96 (C of ester carbonyl), 160.16 (C2 of coumarin), 
154.01 (C9 of coumarin), 142.80 (C7 of coumarin), 
140.98 (C2 of imidazole), 140.22 (Ar-C), 138.94  
(Ar-C), 134.30 (C4 of imidazole), 130.32 (Ar-C), 
129.90 (Ar-C), 128.70 (Ar-C), 128.62 (Ar-C), 128.44 
(Ar-C), 128.38 (Ar-C), 128.32 (Ar-C), 128.28 (Ar-C), 
127.22 (Ar-C), 127.08 (Ar-C), 125.96 (Ar-C), 125.47 
(Ar-C), 124.28 (C5 of imidazole), 123.47 (Ar-C), 
122.46 (Ar-C), 116.72 (Ar-C), 114.14 (C5 of 
coumarin), 113.40 (C6 of coumarin), 112.44 (Ar-C), 
112.12 (Ar-C), 112.10 (C8 of coumarin), 112.05 (C3 
of coumarin), 112.00 (C10 of coumarin), 58.94 (CH3 
of ester), 21.02 (CH3 of coumarin). 
Methyl-4-(2-(6-methoxy-2-oxo-2H-chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7c: White 
solid. Yield 90%. m.p.186-188°C. IR (KBr): 1701, 
1674 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.44 (s, 
1H), 8.04 (d, J = 8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 2H), 
7.46 (d, J = 8 Hz, 2H), 7.37 (d, J = 8 Hz, 2H), 7.34 
(m, 6H), 7.28 (d, J = 8 Hz, 1H), 7.32 (s, 1H), 6.78 (d, 
J = 12 Hz, 1H), 6.56 (d, J = 8 Hz, 1H), 4.20 (s, 3H), 
3.84 (s, 3H); 13C NMR (100 MHz, DMSO-d6): δ 
174.92 (C of ester carbonyl), 160.14 (C2 of coumarin), 
153.98 (C9 of coumarin), 142.79 (C7 of coumarin), 
140.98 (C2 of imidazole), 140.22 (Ar-C), 138.94  
(Ar-C), 134.30 (C4 of imidazole), 130.32 (Ar-C), 
129.92 (Ar-C), 128.71 (Ar-C), 128.62 (Ar-C), 128.44 
(Ar-C), 128.40 (Ar-C), 128.31 (Ar-C), 127.48 (Ar-C), 
126.47 (Ar-C), 126.04 (Ar-C), 125.88 (C5 of 
imidazole), 124.47 (Ar-C), 124.21 (Ar-C), 123.22 
(Ar-C), 123.10 (Ar-C), 122.96 (Ar-C), 125.26 (C5 of 
coumarin), 121.30 (C6 of coumarin), 116.72 (Ar-C), 
114.12 (Ar-C), 113.40 (C8 of coumarin), 111.44 (C3 
of coumarin), 110.82 (C10 of coumarin), 58.98 (CH3 
of ester), 52.10 (OCH3 of coumarin). 
Methyl-4-(2-(6–bromo-2-oxo-2H-chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7d: White 
solid. Yield 78%. m.p.192-194°C. IR (KBr): 1702, 
1670 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.42 (s, 
1H), 8.08 (d, J = 8 Hz, 1H), 7.84 (d, J = 8.8 Hz, 7H), 
7.46 (d, J = 8 Hz, 1H), 7.32 (d, J = 8 Hz, 1H), 7.38 
(m, 4H), 7.34 (d, J = 8 Hz, 1H), 7.28 (s, 1H), 6.76 (d, 
J = 12 Hz, 1H), 4.22 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 174.98 (C of ester carbonyl), 160.18 (C2 
of coumarin), 154.00 (C9 of coumarin), 142.82 (C7 of 
coumarin), 141.00 (C2 of imidazole), 140.24 (Ar-C), 
138.96 (Ar-C), 134.32 (C4 of imidazole), 130.34  
(Ar-C), 129.92 (Ar-C), 128.74 (Ar-C), 128.64 (Ar-C), 
128.42 (Ar-C), 128.39 (Ar-C), 127.24 (Ar-C), 127.11 
(Ar-C), 127.00 (Ar-C), 125.98 (Ar-C),124.56 (C4 of 
imidazole), 124.50 (Ar-C), 124.42 (Ar-C), 124.31 
(Ar-C), 123.71 (Ar-C), 123.00 (Ar-C), 122.58 (C5 of 
coumarin), 122.30 (C6 of coumarin), 116.70 (Ar-C), 
114.16 (Ar-C), 113.42 (C8 of coumarin), 111.46 (C3 
of coumarin), 110.84 (C10 of coumarin), 58.96 (CH3 
of ester). 
Methyl-4-(2-(6-chloro-2-oxo-2H-chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7e: White 
solid. Yield 74%. m.p.190-192°C. IR (KBr): 1700, 
1672 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.44 (s, 
1H), 8.06 (d, J = 8 Hz, 1H), 7.86 (d, J = 8.8 Hz, 7H), 
7.44 (d, J = 8 Hz, 1H), 7.33 (d, J = 8 Hz, 1H), 7.40 
(m, 4H), 7.36 (d, J = 8 Hz, 1H), 7.30 (s, 1H), 6.78 (d, 
J = 12 Hz, 1H), 4.24 (s, 3H); 13C NMR (100 MHz, 
DMSO-d6): δ 175.02 (C of ester carbonyl), 160.20 (C2 
of coumarin), 154.02 (C9 of coumarin), 142.84 (C7 of 
coumarin), 141.02 (C2 of imidazole), 140.26 (Ar-C), 
138.98 (Ar-C), 134.34 (C4 of imidazole), 130.36  
(Ar-C), 129.93 (Ar-C), 128.75 (Ar-C), 128.66 (Ar-C), 
128.44 (Ar-C), 128.40 (Ar-C), 127.26 (Ar-C), 127.15 
(Ar-C), 127.02 (Ar-C), 125.99 (Ar-C), 124.59 (C4 of 
imidazole), 124.51 (Ar-C), 124.42 (Ar-C), 124.32 
(Ar-C), 123.71 (Ar-C), 123.00 (Ar-C), 122.58 (C5 of 
coumarin), 122.30 (C6 of coumarin), 116.72 (Ar-C), 
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114.18 (Ar-C), 113.44 (C8 of coumarin), 111.45 (C3 
of coumarin), 110.86 (C10 of coumarin), 59.02 (CH3 
of ester). 
Methyl-4-(2-(2-oxo-2H-benzo[h]chromen-4-yl)-
4,5-diphenyl-1H-imidazol-1-yl)benzoate 7f: White 
solid. Yield 80%. m.p.194-196°C. IR (KBr): 1700, 
1674 cm−1; 1H NMR (400 MHz, DMSO-d6): δ 8.44 (s, 
1H), 8.06 (d, J = 8 Hz, 1H), 7.86 (d, J = 8.8 Hz, 7H), 
7.45 (d, J = 8 Hz, 2H), 7.32 (d, J = 8 Hz, 2H), 7.40 
(m, 4H), 7.36 (d, J = 8 Hz, 1H), 7.30 (s, 1H), 6.78 (d, 
J = 12 Hz, 1H), 6.54 (d, J = 8 Hz, 1H), 4.24 (s, 3H); 
13C NMR (100 MHz, DMSO-d6): δ 174.90 (C of ester 
carbonyl), 160.22 (C2 of coumarin), 158.04 (C4 of 
coumarin), 154.84 (C13 of coumarin), 141.02 (Ar-C), 
140.26 (C2 of imidazole), 138.98 (C12 of coumarin), 
134.34 (Ar-C), 130.35 (Ar-C), 129.94 (C2 of 
imidazole),129.88 (Ar-C), 129.67 (Ar-C), 128.75  
(Ar-C), 128.70 (Ar-C), 128. 69 (Ar-C), 128.66  
(Ar-C), 128.60 (Ar-C), 128.53 (Ar-C), 128.44 (Ar-C), 
128.40 (Ar-C), 128.00 (Ar-C), 127.25 (Ar-C), 127.11 
(Ar-C), 127. 09 (Ar-C), 127.02 (Ar-C), 127.00 (Ar-C), 
126.96 (C8 of coumarin), 126.50 (C9 of coumarin), 
125.32 (C11 of coumarin), 124.47 (C2 of imidazole), 
116.72 (Ar-C), 114.18 (C6 of coumarin), 113.44 (C10 
of coumarin), 111.45 (C3 of coumarin), 110.85 (C14 of 
coumarin), 59.12 (CH3 of ester). 
 
Conclusion 
Coumarin and its derivatives are key antimicrobial 
ingredients in several antibiotics, here we have 
successfully synthesized a pharmacophore library of 
coumarin-imidazole conjugates 4a-g, 4h-m, 6a-f and 
7a-f both in conventional as well microwave 
irradiation method. The conjugates were evaluated for 
their antibacterial and antifungal activities. Most of 
the compounds exhibited promising activity with MIC 
values 0.1 to 0.7µg/mL against bacterial and fungal 
strains, while compounds 4b, 4k and 6a are not active 
at a selected MIC values. The molecular docking 
study shows excellent interaction score values in 
agreement with most active compounds. 
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